
TEM Stock Forecast & Price Target
TEM Analyst Ratings
Bulls say
Tempus AI Inc. has demonstrated robust financial growth, with total revenue increasing by 84.7% year-over-year, primarily fueled by a significant 117.2% rise in genomics revenue, which reached $252.9 million. The company is poised for further revenue enhancement through potential new pharmaceutical contracts and an expected shift towards higher average selling prices (ASPs) for its xF liquid biopsy and xT CDx tests. Additionally, the notable increase in oncology testing volume, with 87.5k NGS tests conducted in Q3 2025, reflects a strong demand for its innovative diagnostic solutions.
Bears say
The key points contributing to a negative outlook on Tempus AI Inc.’s stock are centered around financial performance and risks. The company experienced a decline in gross margins in its Data & Other segment, dropping from 76.8% in Q3 2024 to 69.7% in Q3 2025, signaling potential challenges in maintaining profitability in a competitive market. Additionally, Tempus continues to incur significant losses, has a substantial amount of debt on its balance sheet, and its operating cash flow saw a concerning decrease of $168.5 million year-over-year, raising doubts about its ability to achieve sustainable growth and profitability in the future.
This aggregate rating is based on analysts' research of Tempus AI Inc and is not a guaranteed prediction by Public.com or investment advice.
TEM Analyst Forecast & Price Prediction
Start investing in TEM
Order type
Buy in
Order amount
Est. shares
0 shares